Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
BTK inhibitors: toxicity, resistance, and combinations
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Exciting advances in checkpoint inhibitors, CAR T-cells and ALK inhibitors
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors